Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17440954 | 1.00 | GPR3 (0.35) | GPR3 | |
| SCHEMBL17440952 | 1.00 | GPR3 (0.35) | GPR3 | |
| SCHEMBL16700407 | 1.00 | GPR3 (0.35) | GPR3 | |
| SCHEMBL16700406 | 1.00 | GPR3 (0.35) | GPR3 | |
| SCHEMBL18717568 | 0.89 | GPR3 (0.33) | GPR3 | |
| SCHEMBL20880442 | 0.89 | GPR3 (0.33) | GPR3 | |
| SCHEMBL31091548 | 0.88 | GPR3 (0.37) | GPR3 | |
| SCHEMBL15357241 | 0.88 | GPR3 (0.37) | GPR3 | |
| SCHEMBL8281426 | 0.88 | GPR3 (0.37) | GPR3 | |
| SCHEMBL14778869 | 0.84 | GPR3 (0.39) | GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351584-B2 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-07-08 | — | — | US | disclosed |
| CN-114181213-B | Cyclic ether derivatives of pyrazolo [1,5-a ] pyrimidine-3-carboxamide | 勃林格殷格翰国际有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20230286993-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INT (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230286993-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INT (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230286993-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INT (DE) | 2023-09-14 | — | — | US | disclosed |
| US-11691977-B2 | Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-04 | — | — | US | disclosed |
| US-11691977-B2 | Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-04 | — | — | US | disclosed |
| US-11691977-B2 | Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-04 | — | — | US | disclosed |
| EP-3362453-B1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INT (DE) | 2022-03-30 | — | — | EP | disclosed |
| CN-114181213-A | Cyclic ether derivatives of pyrazolo [1,5-a ] pyrimidine-3-carboxamides | 勃林格殷格翰国际有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-20170101411-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-04-13 | — | — | US | disclosed |
| US-20170101411-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-04-13 | — | — | US | disclosed |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-05 | — | — | US | disclosed |
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| WO-2016011390-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2015073763-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | GPR3 3402/4885 |
| US-20230286993-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | CNP, PDE3A, PDE5A | GPR3 1228/4885 |
| US-20170101411-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | CNP, PDE5A, PDE3A | GPR3 1755/4885 |
| US-11691977-B2 | Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide | CNP, PDE5A, PDE3A | GPR3 1755/4885 |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | GPR3 3402/4885 |
| US-12351584-B2 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | CNP, PDE3A, PDE5A | GPR3 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.